Euglena Management

Management criteria checks 2/4

Euglena's CEO is Tomohiro Wakahara, appointed in Jan 2021, has a tenure of 3.83 years. directly owns 0.013% of the company’s shares, worth ¥7.81M. The average tenure of the management team and the board of directors is 2.8 years and 5.9 years respectively.

Key information

Tomohiro Wakahara

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	3.8yrs
CEO ownership	0.01%
Management average tenure	2.8yrs
Board average tenure	5.9yrs

Recent management updates

Recent updates

Would Euglena (TSE:2931) Be Better Off With Less Debt?

Nov 13

CEO

Tomohiro Wakahara

3.8yrs

Tenure

Mr. Tomohiro Wakahara is Representative Executive Officer at Euglena Co., Ltd. since 2018 and serves as Co-Chief Executive Officer since 2024. He serves as Director at Euglena Co., Ltd.He served as its M...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Tomohiro Wakahara	Representative Executive Officer	3.8yrs	no data	0.013% ¥ 7.8m
Hiroko Uemura	Representative Executive Officer	less than a year	no data	0.0029% ¥ 1.7m
Mitsuru Izumo	Founder	no data	no data	9.03% ¥ 5.3b
Kengo Suzuki	Executive Officer & CTO	2.8yrs	no data	0.87% ¥ 514.5m
Daisuke Susa	Executive Officer & Chief Administrative Officer	no data	no data	no data
Satake Yukoh	Executive Officer & Chief Legal Officer	less than a year	no data	no data
Korehiro Odate	Executive Officer & Head of Energy Company	6.8yrs	no data	no data
Shoko Takahashi	Executive Officer & Bioinformatics Business Head	6.8yrs	no data	no data
Yasuhiro Fukutomi	Special Officer & CSO	2.8yrs	no data	no data
Yukihiro Maru	Professional Officer & CRO	2.8yrs	no data	no data
Yuichi Hoshino	Executive Officer & CIO	2.8yrs	no data	no data
Midori Watabe	Chief Future Officer	2.8yrs	no data	no data

2.8yrs

Average Tenure

44yo

Average Age

Experienced Management: 2931's management team is considered experienced (2.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Tomohiro Wakahara	Representative Executive Officer	no data	no data	0.013% ¥ 7.8m
Hiroko Uemura	Representative Executive Officer	less than a year	no data	0.0029% ¥ 1.7m
Mitsuru Izumo	Founder	19.3yrs	no data	9.03% ¥ 5.3b
Etsuko Okajima	Director	6.8yrs	no data	0.021% ¥ 12.6m
Makoto Shimizu	Independent Outside Director	8.9yrs	no data	no data
Mirai Murakami	Independent Outside Director	3.9yrs	no data	no data
Masahiro Kotosaka	Independent Outside Director	5.9yrs	no data	0.019% ¥ 11.3m
Aiko Mochizuki	Independent Outside Director	3.9yrs	no data	no data

5.9yrs

Average Tenure

44.5yo

Average Age

Experienced Board: 2931's board of directors are considered experienced (5.9 years average tenure).

Euglena Management

Management criteria checks 2/4

Key information

Recent management updates

Euglena Co., Ltd., Annual General Meeting, Mar 19, 2024

Insufficient new directors

Euglena Co., Ltd., Annual General Meeting, Mar 24, 2023

Euglena Co., Ltd., Annual General Meeting, Mar 26, 2022

Euglena Co., Ltd., Annual General Meeting, Dec 18, 2020

Recent updates

Third quarter 2024 earnings released: JP¥5.73 loss per share (vs JP¥2.98 loss in 3Q 2023)

Would Euglena (TSE:2931) Be Better Off With Less Debt?

Euglena Co., Ltd. to Report Q3, 2024 Results on Nov 11, 2024

Euglena Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ended December 31, 2024

New minor risk - Share price stability

Euglena Co., Ltd. to Report Q2, 2024 Results on Aug 08, 2024

Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2024

First quarter 2024 earnings released: EPS: JP¥1.48 (vs JP¥1.45 loss in 1Q 2023)

Euglena Co., Ltd. to Report Q1, 2024 Results on May 13, 2024

Full year 2023 earnings released: JP¥22.75 loss per share (vs JP¥23.83 loss in FY 2022)

Euglena Co., Ltd., Annual General Meeting, Mar 19, 2024

Full year 2023 earnings released: JP¥22.75 loss per share (vs JP¥23.83 loss in FY 2022)

Zenhoren Co.,Ltd. (TSE:5845) agreed to acquire 18.93% stake in Okinawa Basketball Co., Ltd from Euglena Co., Ltd. (TSE:2931) for ¥360 million.

Euglena Co., Ltd. (TSE:2931) agreed to acquire Saticine Medical Co., Ltd.

Insufficient new directors

Euglena Co., Ltd. to Report Fiscal Year 2023 Results on Feb 14, 2024

Third quarter 2023 earnings released: JP¥2.98 loss per share (vs JP¥15.91 loss in 3Q 2022)

Euglena Co., Ltd. to Report Q3, 2023 Results on Nov 13, 2023

Second quarter 2023 earnings released

Euglena Co., Ltd. to Report Q2, 2023 Results on Aug 14, 2023

First quarter 2023 earnings released

Full year 2022 earnings released: JP¥23.83 loss per share (vs JP¥44.51 loss in FY 2021)

Price target increased by 11% to JP¥1,000

Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending Dec. 31, 2023

Euglena Co., Ltd., Annual General Meeting, Mar 24, 2023

Full year 2022 earnings released: JP¥23.83 loss per share (vs JP¥44.51 loss in FY 2021)

Euglena Co., Ltd. announced that it has received ¥7.7999475 billion in funding from Marui Group Co., Ltd., Rohto Pharmaceutical Co.,Ltd., Mazda Motor Corporation, Dai-ichi Life Holdings, Inc.

Euglena Co., Ltd. announced that it expects to receive ¥7.7999475 billion in funding from Marui Group Co., Ltd., Rohto Pharmaceutical Co.,Ltd.

Euglena Co., Ltd. to Report Fiscal Year 2022 Results on Feb 13, 2023

Euglena Co., Ltd. Provides Consolidated Financial Guidance for the Year Ending December 31, 2022

Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022

Euglena Co., Ltd. to Report Q2, 2022 Results on Aug 10, 2022

Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022

Euglena Co., Ltd. to Report Q1, 2022 Results on May 13, 2022

Full year 2021 earnings released: JP¥39.26 loss per share (vs JP¥17.15 loss in FY 2020)

Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022

Euglena Co., Ltd., Annual General Meeting, Mar 26, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Euglena Co., Ltd. Provides Earnings Guidance for the Period from October 1, 2020 to December 31, 2021

Euglena Co., Ltd. Provides Consolidated Sales Guidance for the Full Year Ending September 30, 2021

Second quarter 2021 earnings released: EPS JP¥1.75 (vs JP¥1.17 in 2Q 2020)

Euglena Co., Ltd., Chevron Lummus Global and Applied Research Associates, Inc. Announce Successful Production of Renewable Jet Fuel

New 90-day high: JP¥1,264

Euglena Co., Ltd. to Report Q2, 2021 Results on May 14, 2021

First quarter 2021 earnings released: JP¥3.87 loss per share (vs JP¥2.71 loss in 1Q 2020)

New 90-day high: JP¥909

Euglena Co., Ltd. (TSE:2931) entered into an agreement to acquire Liguna, K.K. from Noriko Minamizawa and Takeshi Matsumoto.

Euglena Co., Ltd. to Report Q1, 2021 Results on Feb 15, 2021

Full year 2020 earnings released: JP¥16.00 loss per share

New 90-day low: JP¥774

The fund managed by Advantage Partners, Inc., Euglena Co., Ltd. (TSE:2931) and Tokyo Century Corporation (TSE:8439) agreed to acquire Q' Sai Co., Ltd. from Coca-Cola Bottlers Japan Holdings Inc. (TSE:2579).

New 90-day low: JP¥797

Euglena Co., Ltd., Annual General Meeting, Dec 18, 2020

Euglena Co., Ltd. to Report Fiscal Year 2020 Results on Nov 13, 2020

Euglena Co., Ltd. (TSE:2931) cancelled the acquisition of MEJ Inc. from Toru Koga and others.

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age